Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyAetna Body Surface Potential Mapping Coverage | Op…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0705

    Body Surface Potential Mapping

    Customize your policy alerts

    Sign up for Aetna Policy 0705 alerts

    Get alerted when Policy 0705 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the coverage stance for body surface potential mapping (BSPM) procedures and related CPT/HCPCS/ICD-10 codes for Aetna members.

    Policy Summary
    PayerAetna
    PolicyBody Surface Potential Mapping
    Policy CodePolicy 0705
    Change TypeNo material change
    Effective DateJun 7, 2005
    Last ReviewOct 13, 2023
    Next Review DateAug 8, 2024
    Key ActionWhen submitting claims, include procedure code(s) describing BSPM or related device interrogation/programming and supporting clinical documentation describing the indication.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    64-120electrodes (typical)
    Experimental/Investigationalcoverage stance
    PRIME‑ECGexample system
    66CRT study size
    80leads in OCCULT‑MI study

    Coverage Criteria — Experimental / Investigational Indications

    Experimental/Investigational Indications

    Aetna considers BSPM experimental and investigational for the following indications because effectiveness has not been established:

    Listed indications considered experimental/investigational: 1. Evaluation of acute coronary syndromes (e.g., acute cardiac ischemia and myocardial infarction); 2. Evaluation of atrial fibrillation; 3. Evaluation of Brugada syndrome; 4. Guidance of atrial fibrillation ablation; 5. Prediction of response in cardiac resynchronization therapy.

    Not an all-inclusive list; effectiveness not established

    Aetna considers body surface potential mapping (BSPM) experimental and investigational for the following indications because effectiveness has not been established: 1) evaluation of acute coronary syndromes (for example, acute cardiac ischemia and myocardial infarction); 2) evaluation of atrial fibrillation; 3) evaluation of Brugada syndrome; 4) guidance of atrial fibrillation ablation; and 5) prediction of response to cardiac resynchronization therapy (CRT). Services for these indications may be denied as experimental and investigational.

    UpToDate reviews cited in the evidence summary do not mention body surface potential mapping as a management tool for atrial fibrillation ablation or for Brugada syndrome; specifically, multiple UpToDate reviews on catheter and surgical ablation for atrial fibrillation do not reference BSPM for guiding AF ablation, and an UpToDate review on Brugada syndrome does not mention body surface mapping as a management strategy.

    Available studies report preliminary findings suggesting potential roles for BSPM (for example, complex network metrics to predict atrial fibrillation recurrence and BSPM-derived metrics to predict CRT response), but the policy notes these observations are preliminary and explicitly states that such findings need validation in well-designed studies before routine clinical use can be supported.

    Evidence observations

    Summary of clinical findings and limitations from cited studies

    Evidence observations: Small observational and pilot studies report potential applications of BSPM including: guidance of atrial fibrillation ablation (UpToDate reviews do not mention BSPM for AF ablation), mapping activation patterns in Brugada syndrome using multi‑lead recordings, prediction of CRT response via SDAT (standard deviation of activation times) with reported SDAT >=35 ms and >=10% SDAT improvement associated with greater EF/LVESV changes, detection of ischemia during exercise with HR‑BSPM showing modestly higher sensitivity/specificity than standard 12‑lead ECG, and exploratory complex‑network metrics from BSPM that may predict AF recurrence; however, these findings are preliminary, limited by small sample sizes and observational designs, and require validation in well‑designed studies.

    Derived from multiple background sections; preliminary evidence only

    Coding — CPT, HCPCS, and ICD-10 Codes

    CPT codes not covered for CPB-listed indicationsCPTNot Covered
    0695TBody surface–activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement.
    0696TBody surface–activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation.
    Other related CPT codes referencedCPT
    33208Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial and ventricular.
    33214Upgrade of implanted pacemaker system, conversion of single chamber system to dual chamber system (includes removal of previously placed pulse generator, testing of existing lead, insertion of new lead, insertion of new pulse generator).
    33224Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with attachment to previously placed pacemaker or implantable defibrillator pulse generator (including revision of pocket, removal, insertion, and/or replacement of existing generator).
    33225Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) (List separately in addition to code for primary procedure).
    33229Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator; multiple lead system.
    33249Insertion or replacement of permanent implantable defibrillator system, with transvenous lead(s), single or dual chamber.
    33263
    33264Removal of implantable defibrillator pulse generator with replacement of implantable defibrillator pulse generator.
    93000-93278Cardiography.
    93281-93284Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional.
    1–10 of 15
    1/2
    Related HCPCS codesHCPCS
    C7537Insertion of new or replacement of permanent pacemaker with atrial transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable debribrillator or pacemake pulse generator (eg, for upgrade to dual chamber system).
    C7538Insertion of new or replacement of permanent pacemaker with ventricular transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defribrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system).
    C7539Insertion of new or replacement of permanent pacemaker with atrial and ventricular transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system).
    C7540Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator, dual lead system, with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system).
    ICD-10 codes not covered for CPB-listed indicationsICD-10Not Covered
    I00-I52Heart disease
    No codes listed in this document sectionmixed
    No codes listed
    SDAT threshold
    SDAT threshold>= 35 ms predicts changes in EF after CRT
    Study sample size66 patients (Gage et al., 2017)
    Electrode count in CRT maps53 anterior and posterior electrodes used to construct body surface isochronal maps
    SDAT percent change
    SDAT percent change associated with response>= 10% improvement in SDAT associated with greater changes in EF and LVESV after CRT
    EF change with >=10% SDAT improvement

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Prior Authorization

    Prior authorization not specified in this portion of the policy. The document does not list any specific CPT or HCPCS codes that require prior authorization for body surface potential mapping procedures.

    • Prior authorization: Not specified
    Denial Risk

    Denial Risk for Listed Indications

    Services billed for body surface potential mapping (BSPM) for the indications listed in this policy (e.g., evaluation of acute coronary syndromes, atrial fibrillation, Brugada syndrome, guidance of atrial fibrillation ablation, prediction of response in cardiac resynchronization therapy) are considered experimental and investigational and may be denied.

    • Denial risk: BSPM for listed indications may be denied as experimental/investigational

    Background — What is Body Surface Potential Mapping (BSPM)

    Body surface potential mapping is an electrophysiologic technique that records cardiac electrical activity from a much larger surface area than the conventional 12-lead ECG by using many more electrodes on the torso—typically 64 up to approximately 120 electrodes—to generate detailed surface potential maps and three-dimensional representations of cardiac electrical activation.

    Definitions and Key Terms

    Body surface potential mapping (BSPM)
    DefinitionElectrophysiologic technique using multiple torso electrodes (typically 64 up to ~120) to record cardiac electrical activity across a larger surface area than the standard 12‑lead ECG, generating comprehensive 3‑dimensional surface potential maps.
    Typical electrode countsCommonly 64 or more electrodes; may use up to ~120 electrodes.
    Primary uses investigatedDetection/localization of ischemia, infarct sizing, arrhythmia mapping, guidance of ablation, and CRT response assessment.
    PRIME‑ECG
    Example systemPRIME‑ECG — a BSPM system cleared by the FDA through the 510(k) process (Meridian Medical Technologies / Heartscape Technologies).
    Regulatory statusIdentified among devices cleared for marketing by the FDA in technology assessments; PRIME‑ECG commercially available and 510(k) cleared.
    Policy Summary
    PayerAetna
    PolicyBody Surface Potential Mapping
    Policy CodePolicy 0705
    Change TypeNo material change
    Effective DateJun 7, 2005
    Last ReviewOct 13, 2023
    Next Review DateAug 8, 2024
    Key ActionWhen submitting claims, include procedure code(s) describing BSPM or related device interrogation/programming and supporting clinical documentation describing the indication.
    SourceLink
    On This Page
    Coverage Criteria — Experimental / Investigational IndicationsCoding — CPT, HCPCS, and ICD-10 CodesProvider Actions, Authorization, and DocumentationBackground — What is Body Surface Potential Mapping (BSPM)Definitions and Key Terms
    11 ± 9 units versus 4 ± 9 units (p = 0.010)
    LVESV change with >=10% SDAT improvement-33% ± 26% versus -6% ± 34% (p = 0.001)
    Documentation Required

    Documentation and Claim Guidance

    No specific documentation requirements are stated in this portion of the policy. When submitting claims, include applicable procedure code(s) and supporting documentation (e.g., clinical indication, reports) as appropriate to substantiate medical necessity.

    • Documentation: No specific documentation requirements stated
    • Claim guidance: Include procedure code(s) and supporting documentation when submitting claims
    Step Therapy

    Step Therapy

    No step therapy requirements are described in this portion of the policy.

    • Step therapy: None specified
    Note

    Provider Authorization

    No explicit provider authorization or additional prior authorization requirements are specified in this portion of the document.

    • Provider authorization: Not specified
    Role in evidence basePRIME‑ECG featured in assessments as demonstrating proof of concept but requiring further research to define clinical utility.
    SDAT (standard deviation of activation times)
    DefinitionStandard deviation of activation times (SDAT) — a metric derived from BSPM that quantifies electrical dyssynchrony across body surface activation times.
    Clinical relevanceSDAT has been reported to predict response to cardiac resynchronization therapy (CRT) better than QRS duration in studied cohorts.
    Association with outcomesHigher SDAT values and reductions in SDAT after pacing correlated with greater improvements in left ventricular ejection fraction and reductions in LVESV.
    HR‑BSPM (high‑resolution BSPM)
    DefinitionHigh‑resolution body surface potential mapping (HR‑BSPM) — a multi‑lead BSPM configuration (e.g., 67 leads) used during exercise testing to detect ischemic changes not captured by standard 12‑lead ECG positions.
    Electrode count example67‑lead HR‑BSPM used in exercise studies comparing to 12‑lead ECG.
    Diagnostic performanceHR‑BSPM parameters (ΔST60 and δT) showed higher sensitivity/specificity (e.g., 70/69% for ΔST60) than standard 12‑lead ECG in one study.